Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
站內檢索
:::

李重賓 (Chung-Pin Li)

李重賓(Chung-Pin Li)圖 Return Appointment First Appointment

[簡介]

  • 學歷
    • Ph.D., Institute of Clinical Medicine; National Yang-Ming University School of Medicine, Taipei, Taiwan ,
    • M.D., National Yang-Ming University School of Medicine, Taipei, Taiwan,
  • 經歷
    現職：
    • - Now, Attending Physician, Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan ,
    • - Now, Professor, National Yang-Ming University School of Medicine, Taipei, Taiwan ,
    經歷：
    • - , post-doc fellow, Division of GI/Liver Pathology, Department of Pathology, Johns Hopkins University School of Medicine, MD ,
    • - , Chief Resident, Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan ,
    • - , Resident, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan ,
  • 醫療專長
    1. Pancreatic cancer
    2. GI tract cancers
    3. Chronic hepatitis B and C
    4. Liver cirrhosis and its complications
    5. Abdominal ultrasound and GI tract endoscopy

[著作]

  1. Li CP, Chia-Chi Chen, Li-Li Chen, Yu-Ting Hsu, Shih-Sheng Jiang, Chi-Shuan Fan, Kee Voon Chua, Sheng-Xiang Huang, Yi-Ming Shyr, Li-Tzong Chen & Tze-Sing Huang. Myeloid-Derived Macrophages and Secreted HSP90α Induce Pancreatic Ductal Adenocarcinoma Development. Oncoimmunology 2018 Jan. 9;  7(5), e1424612.(IF: 7.719, Oncology: 20/217)
  2. Wu CY, Hu HY, Chou YJ, Huang N, Chou YC, Li CP* (correspondent). What constitutes normal hemoglobin concentrations among community-dwelling older adults? Journal of the American Geriatrics Society 2016 Jun;64(6):1233-41. (IF= 4.388；R/C= 2/32, GERONTOLOGY)
  3. Wang JP, Wu CY, Hwang IH, Kao CH, Hung YP, Hwang SJ, Li CP* (correspondent). How different is the care of terminal pancreatic cancer patients in inpatient palliative care units and acute hospital wards? A nationwide population-based study. BMC Palliative Care 2016 Jan 8;15(1):1 (IF=1.602, R/C= 46/88, HEALTH CARE SCIENCES & SERVICES).
  4. Chen MH, Lin J, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP* (correspondent), Chao Y. A Phase II Study of Sequential Capecitabine plus Oxaliplatin Followed by Docetaxel plus Capecitabine in Patients with Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial. Medicine 2016 Jan;95(3):e2565 (IF=1.804, R/C= 40/155, Medicine, General & Internal).
  5. Wu CY, Hu HY, Chou YJ, Huang N, Chou YC, Li CP* (correspondent). High Blood Pressure and All-cause and Cardiovascular Disease Mortalities in Community-dwelling Older Adults. Medicine 2015 Nov;94(47):e2160 (IF=1.804, R/C= 40/155, Medicine, General & Internal).
  1. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators (Li CP). Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18. (IF= 24.690；R/C= 3/211, ONCOLOGY)
  2. Chen JS, Hsu C, Chiang NJ, Tsai CS, Tsou HH, Huang SF, Bai LY, Chang IC, Shiah HS, Ho CL, Yen CJ, Lee KD, Chiu CF, Rau KM, Yu MS, Yang Y, Hsieh RK, Chang JY, Shan YS, Chao Y, Chen LT; Taiwan Cooperative Oncology Group (Li CP). A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. ANNALS OF ONCOLOGY. 2015 May;26(5):943-9. doi: 10.1093/annonc/mdv035. Epub 2015 Jan 28. (IF= 7.040；R/C= 18/211, ONCOLOGY)
  3. Wu CY, Hu HY, Chou YJ, Huang N, Chou YC, MS Lee, Li CP* (correspondent). High Serum Uric Acid Levels Are Associated with All-Cause and Cardiovascular, but Not Cancer, Mortality in Elderly Adults. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY 2015 Sep;63(9):1829-36. doi: 10.1111/jgs.13607. Epub 2015 Aug 16. (IF=4.388；R/C= 2/32, GERONTOLOGY)
  4. Yeh PW, Hsieh YC, Li CP, Chao Y, Hou MC, Lin HC, Lee KC. Self-expandable metallic stent placement in malignant gastric outlet obstruction: a comparison between two brands of stents. Medicine 2015 Jul;94(29):e1208. doi: 10.1097/MD.0000000000001208. (IF=5.723, R/C= 15/154, Medicine, General & Internal).
  5. Wu CY, Hu HY, Chow LH, Chou YJ, Huang N, Wang PN, Li CP* (correspondent). The effects of anti-dementia and nootropic treatments on the mortality of patients with dementia: a population-based cohort study in Taiwan. PLOS ONE 2015 Jun 22;10(6):e0130993. doi: 10.1371/journal.pone.0130993. (IF= 3.234；R/C= 9/57, Multidiscipline Medicine) (Times cited:  )
  6. Wu CY, Chang WP, Chang YH, Li CP* (correspondent), Chuang CM. The risk of irritable bowel syndrome in patients with endometriosis during a 5-year follow-up: a nationwide population-based cohort study. International Journal of Colorectal Disease 2015 Jul;30(7):907-12. 2015 Apr 28. (IF= 2.449；R/C= 55/198, 27.8%, Surgery) (Times cited:  )
  7. Wang JP, Wu CY, Yeh YC, Shyr YM, Wu YY, Kuo CY, Hung YP, Chen MH, Lee WP, Luo JC, Chao Y, Li CP* (correspondent). Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget 2015 Jul 20;6(20):18162-73. (IF= 5.008；R/C= 36/213, Oncology) (Times cited:  ) (V103C-201, NSC 98-2314-B-075-029)
  8. Wu CY, Hu HY, Chou YC, Huang N, Chou YJ, Li CP* (correspondent). The association of physical activity with all-cause, cardiovascular, and cancer mortality among older adults. Preventive Medicine 2015 Mar;72:23-9. (IF= 3.434；R/C= 24/155, MEDICINE, GENERAL & INTERNAL)
  9. Wang JP, Kao FY, Wu CY, Hung YP, Chao Y, Chou YJ, Li CP* (correspondent). Nucleos(t)ide analogs associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study. Cancer 2015 May 1;121(9):1446-55. (I F= 5.649；R/C=26/213, ONCOLOGY)